Hepatocellular carcinoma
Conditions
Interventions
Transcatheter Arterial Chemoembolization (TACE) Combined with Targeted Therapy and Immunotherapy vs Transcatheter Arterial Chemoembolization (TACE) Combined with Immunotherapy:None
Sponsors
The Fifth Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.The patient and their family members provide informed consent to participate in the study; the patient is willing and able to attend regular follow-up visits and commits to adhering to the follow-up schedule. 2.Aged 18 to 75 years old, with no gender restrictions. 3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2. 4.Confirmed diagnosis of hepatocellular carcinoma (HCC) by two types of imaging examinations or pathological tests. 5.Expected survival time of = 12 weeks (according to the Chinese Clinical Practice Guidelines for Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma, an expected survival of less than 3 months is considered a contraindication for TACE). 6.Treatment-naive patients with no prior history of local therapy or systemic anti-tumor treatment (including TACE, HAIC, chemotherapy, tyrosine kinase inhibitors [TKIs], and immunotherapy). 7.No history of liver transplantation. 8. Child-Pugh Class A or B (total score = 1.5 × 10 ^ 9/L; Platelet count (PLT) >= 50 × 10 ^ 9/L; Hemoglobin (Hb) >= 90g/L. -Liver function: Total bilirubin (TBIL) = 2.8g/dL. -Renal function: creatinine = 50mL/min (calculated according to the Cockcroft Gault formula, Ccr is only calculated when creatinine>1.5 × ULN). -Coagulation function: activated partial thromboplastin time (aPTT) <= 1.5 × ULN; International normalized ratio (INR) or prothrombin time (PT) <= 1.5 × ULN. 10. Having measurable tumor lesions.
Exclusion criteria
Exclusion criteria: 1. Unsuccessful magnetic resonance elastography (MRE) examination (e.g., due to ascites, abdominal distension, or mechanical failure) or loss of MRE data. 2. Complete replacement of liver parenchyma by tumor tissue. 3. Patients with contraindications to imaging examinations. 4. Pregnant or lactating women. 5. Patients with mental illness or cognitive impairment who are unable to cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Disease control rate; | — |
Countries
China
Contacts
Public ContactDong Jinghui
The Fifth Medical Center of the PLA General Hospital
Outcome results
None listed